Page last updated: 2024-08-18

cyclohexanol and Cryptogenic Fibrosing Alveolitis

cyclohexanol has been researched along with Cryptogenic Fibrosing Alveolitis in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Albers, R; Ayala, L; Bahmanyar, S; Bai, A; Benish, B; Bennett, B; Blease, K; Bodine, T; Cathers, BE; Celeridad, M; Chamberlain, P; Clareen, SS; D'Sidocky, N; Delgado, M; Delker, SL; Fan, R; Giegel, D; Hegde, S; Hilgraf, R; Katz, J; Khatsenko, O; Lachowitzer, J; McCarrick, M; Moghaddam, M; Muir, J; Nadolny, L; Plantevin Krenitsky, V; Raymon, H; Sapienza, J; Satoh, Y; Shirley, MA; Tang, Y; Wright, J; Xu, L	1

Studies

Albers, R; Ayala, L; Bahmanyar, S; Bai, A; Benish, B; Bennett, B; Blease, K; Bodine, T; Cathers, BE; Celeridad, M; Chamberlain, P; Clareen, SS; D'Sidocky, N; Delgado, M; Delker, SL; Fan, R; Giegel, D; Hegde, S; Hilgraf, R; Katz, J; Khatsenko, O; Lachowitzer, J; McCarrick, M; Moghaddam, M; Muir, J; Nadolny, L; Plantevin Krenitsky, V; Raymon, H; Sapienza, J; Satoh, Y; Shirley, MA; Tang, Y; Wright, J; Xu, L

Other Studies

1 other study(ies) available for cyclohexanol and Cryptogenic Fibrosing Alveolitis

Article	Year
Discovery of CC-930, an orally active anti-fibrotic JNK inhibitor. Bioorganic & medicinal chemistry letters, 2012, Feb-01, Volume: 22, Issue:3 Topics: Administration, Oral; Animals; Catalytic Domain; Cyclohexanols; Dogs; Enzyme Activation; Enzyme Inhibitors; Haplorhini; Idiopathic Pulmonary Fibrosis; Inhibitory Concentration 50; MAP Kinase Kinase 4; Models, Molecular; Molecular Structure; Purines; Rats; Structure-Activity Relationship	2012

Article

Year

Discovery of CC-930, an orally active anti-fibrotic JNK inhibitor.

Bioorganic & medicinal chemistry letters, 2012, Feb-01, Volume: 22, Issue:3

Topics: Administration, Oral; Animals; Catalytic Domain; Cyclohexanols; Dogs; Enzyme Activation; Enzyme Inhibitors; Haplorhini; Idiopathic Pulmonary Fibrosis; Inhibitory Concentration 50; MAP Kinase Kinase 4; Models, Molecular; Molecular Structure; Purines; Rats; Structure-Activity Relationship

2012